Real-world orkambi study tracks 852 cystic fibrosis patients
NCT ID NCT03475381
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 852 cystic fibrosis patients aged 12 and older who started taking Orkambi outside of a clinical trial. Researchers tracked how many stopped treatment, why, and measured lung function and nutrition over one year. The goal was to see how the drug performs in real-life settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivacaftor+lumacaftor (Orkambi)
- What this could lead to
- If successful, this could confirm that Orkambi helps control cystic fibrosis symptoms and improve lung function in daily use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for one year, so long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adult CF center, Service de Pneumologie, Cochin Hospital
Paris, Paris, 75006, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs